WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Samsung Biologics | July 21, 2021
Kineta, Inc., a clinical-stage biotech firm developing novel immunotherapies in oncology, has signed a strategic partnership agreement with Samsung Biologics, one of the world's top contract development and manufacturing companies (CDMO). To support the IND filing for KVA12.1, Kineta's new anti-VISTA antibody under development to treat solid tumors, Samsung Biologics will offer end-through-end CDMO services ranging from cell line development to cell line development clinical drug substan...
GT Biopharma | December 23, 2020
GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology organization focused in on innovative treatments dependent on the Company's restrictive NK cell engager (TriKE™) innovation stage is satisfied to report the introduction of extra interval information results for the Company's lead therapeutic competitor, GTB-3550, for the treatment of high-risk myelodysplastic syndromes (HR-MDS).
Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, i...
AMPEL BioSolutions | July 07, 2022
AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual's gene expression and provide clinical decision support to physicians for tre...
Adcentrx Therapeutics | February 15, 2022
Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates.
Under the terms of the collaboration, Adcentrx will specify targets against whic...
CELL AND GENE THERAPY
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE